Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma

Jeffrey R. Sawyer, Erming Tian, Christoph J. Heuck, Donald J. Johann, Joshua Epstein, Charles M. Swanson, Janet L. Lukacs, Regina Lichti Binz, Marian Johnson, Gael Sammartino, Maurizio Zangari, Faith E. Davies, Frits van Rhee, Gareth J. Morgan, Bart Barlogie

Blood (2015) 125 (24): 3756–3759.

https://doi.org/10.1182/blood-2015-03-632075

Published: 2015

Includes: Supplemental data

Journal Articles

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease

Jeffrey R. Sawyer, Erming Tian, Christoph J. Heuck, Joshua Epstein, Donald J. Johann, Charles M. Swanson, Janet L. Lukacs, Marian Johnson, Regina Binz, Angela Boast, Gael Sammartino, Saad Usmani, Maurizio Zangari, Sarah Waheed, Frits van Rhee, Bart Barlogie

Blood (2014) 123 (16): 2504–2512.

https://doi.org/10.1182/blood-2013-12-546077

Published: 2014

Includes: Supplemental data

Journal Articles

Fulminant Onset of Acute Leukemia (FOAL) After Total Therapies (TT) for Multiple Myeloma (MM): Absence of MDS Pathological Criteria within 3 Months of Prior MM Follow-up

Zeba N Singh, MD, Jeffrey R Sawyer, Ph.D., Ginell R. Post, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 1458.

https://doi.org/10.1182/blood.V120.21.1458.1458

Published: 2012

Journal Articles

Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5

Frits van Rhee, MD, PhD, Jeffrey R Sawyer, Ph.D., Saad Z Usmani, MD FACP, Sarah Waheed, MD, Christoph Heuck, MD, Alan Mitchell, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 193.

https://doi.org/10.1182/blood.V120.21.193.193

Published: 2012

Journal Articles

Prediction of cytogenetic abnormalities with gene expression profiles

Yiming Zhou, Qing Zhang, Owen Stephens, Christoph J. Heuck, Erming Tian, Jeffrey R. Sawyer, Marie-Astrid Cartron-Mizeracki, Pingping Qu, Jason Keller, Joshua Epstein, Bart Barlogie, John D. Shaughnessy, Jr

Blood (2012) 119 (21): e148–e150.

https://doi.org/10.1182/blood-2011-10-388702

Published: 2012

Includes: Supplemental data

Journal Articles

Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease.

Angela Pennisi, MD, Xin Li, PhD, Maurizio Zangari, MD, Jeffrey R. Sawyer, MD, Fenghuang Zhan, MD, PhD, Bart Barlogie, MD, PhD, John Shaughnessy, PhD, Shmuel Yaccoby, PhD

Blood (2007) 110 (11): 548.

https://doi.org/10.1182/blood.V110.11.548.548

Published: 2007

Journal Articles

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Ichiro Hanamura, James P. Stewart, Yongsheng Huang, Fenghuang Zhan, Madhumita Santra, Jeffrey R. Sawyer, Klaus Hollmig, Maurizio Zangarri, Mauricio Pineda-Roman, Frits van Rhee, Federica Cavallo, Bart Burington, John Crowley, Guido Tricot, Bart Barlogie, John D. Shaughnessy, Jr

Blood (2006) 108 (5): 1724–1732.

https://doi.org/10.1182/blood-2006-03-009910

Published: 2006

Includes: Supplemental data

Journal Articles

Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping

Jeffrey R. Sawyer, Janet L. Lukacs, Nikhil Munshi, K. Raman Desikan, Seema Singhal, Jayesh Mehta, David Siegel, John Shaughnessy, Bart Barlogie

Blood (1998) 92 (11): 4269–4278.

https://doi.org/10.1182/blood.V92.11.4269

Published: 1998

Journal Articles

Jumping Translocations of Chromosome 1q in Multiple Myeloma: Evidence for a Mechanism Involving Decondensation of Pericentromeric Heterochromatin

Jeffrey R. Sawyer, Guido Tricot, Sandy Mattox, Sundar Jagannath, Bart Barlogie

Blood (1998) 91 (5): 1732–1741.

https://doi.org/10.1182/blood.V91.5.1732

Published: 1998

NARROW

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease

Fulminant Onset of Acute Leukemia (FOAL) After Total Therapies (TT) for Multiple Myeloma (MM): Absence of MDS Pathological Criteria within 3 Months of Prior MM Follow-up

Metaphase Cytogenetic Abnormality (CA) Subtypes in Multiple Myeloma (MM) Treated with Front Line Total Therapy (TT) Protocols TT1, TT2, TT3, TT4 and TT5

Prediction of cytogenetic abnormalities with gene expression profiles

Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease.

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping

Jumping Translocations of Chromosome 1q in Multiple Myeloma: Evidence for a Mechanism Involving Decondensation of Pericentromeric Heterochromatin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only